1. Introduction

Respiratory tract infections caused by pathogenic viruses are reported in different seasons all over the world, which are often considered as “forgotten pandemic”[1]. Complicated cases of respiratory infections are treated in hospitals with additional medical support and uncomplicated cases account for millions of visits to family physicians and absence from work and school causing economic burden to the community[2]. Diagnosis of the pathogenic viruses is often overlooked due to the presence of heterogeneous group of viruses in the respiratory tract. Often they are mistreated with antibiotics that complicate overall treatment procedure by rising level of antibiotic resistance. Viruses can infect the upper respiratory airways causing mild infection like cold and flu. Infections can be more serious and complicated once they reach the lower respiratory system. Serious respiratory disorders may be observed in vulnerable groups such as, children, elderly and immunocompromised patients[3]. This review focuses on the previous studies on respiratory tract infections caused by different types of pathogenic viruses.

2. Respiratory tract infection

The development of molecular methods has revolutionised not only the detection of unknown viruses but also the detection of divergent novel viruses of the respiratory tract. A number of previously unknown pathogenic viruses of the respiratory tract for example, human metapneumovirus (hMPV)[4], human coronavirus (hCoV) NL63[5] and HKU1[6], Middle East respiratory syndrome coronavirus (MERS-CoV)[7], and human bocavirus (hBoV)[8] have been reported in the last two decades. Human viral infections may affect all age groups with a range of severity of infections which may depend on different environmental factors and clinical conditions[9]. Respiratory tract infections can be caused by a variety of microorganisms but the majority of such infections are caused by viruses[10]. Some of these viruses such as influenza A may cause severe disease and can lead to pandemic spread with high morbidity and mortality[11]. Other viruses such as bocavirus may cause less severe infection leading to common cold symptoms[12]. The patterns of respiratory tract infections in common cold are complex due to the potential incidence of multiple viruses in respiratory tract infections in humans.

Upper respiratory tract infections (URTI) can be caused by a wide variety of viruses, including rhinovirus, coronavirus, influenza A and B, parainfluenza, respiratory syncytial virus, adenovirus, metapneumovirus, and enterovirus; as well as by bacteria, including Chlamydia pneumoniae, Mycoplasma pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Bordetella
pertrussis, and Haemophilus influenza[13,14]. The clinical symptoms of URTI are highly variable and cannot be used to identify the aetiological agents. Traditional methods for the identification of URTI pathogens, including culture and serology, are effective for many viral pathogens but are laborious and time consuming. Serological tests, for example, immunofluorescence, can be rapid but are often not sensitive or specific enough to detect all varieties of pathogenic viruses. In one study enzyme immunoassays (EIA) and direct immunofluorescence (DIF) assays showed sensitivities of 85% and 60%–80%, respectively, for detection of influenza virus[15]. Although viral culture is generally accepted as the gold standard for diagnosis, PCR based detection was found to be more sensitive[16]. In another study, rhinovirus infection were detected more efficiently by PCR method (51.5%) than culture method (40%)[17]. Similarly, an influenza virus surveillance study showed better detection by TaqMan-PCR (28%) than conventional culture approach (18%)[18]. However, TaqMan-PCR is relatively expensive and is not regularly used for routine laboratory diagnosis of pathogenic viruses.

Viral infections of the respiratory tract can be self-limiting upper respiratory tract infections or more serious forms of lower respiratory tract infections. Rapid and accurate detection of pathogenic viruses of the respiratory tract can help in the early diagnosis of pathogenic viral infection, decrease the duration of hospitalization and reduce management costs, as well as avoiding additional laboratory testing and unnecessary administration of antibiotics[19,20].

2.1. Global picture of respiratory tract viral infections

Respiratory tract infection is a major cause of disease burden compared to other causes of infection[21]. Respiratory tract infection is one of the leading causes of disease and results in mortality rate of 18% in children less than 5 years old. The next most common infections are diarrhoeal diseases (15%) and malaria (11%) around the world[22]. Morbidity due to respiratory tract infection in this age group varies in different parts of the world. It was reported that 22% and 26.7% of all hospitalized patients had respiratory illness in the UK[23] and Belgium[24], respectively. Amongst all other viral infections in humans, influenza was found to be associated with approximately 250,000–500,000 deaths globally each year[25]. The actual mechanism for spread of influenza seasonally worldwide is not clearly understood but is found to be associated with a number of factors including environmental conditions and patient health[26–29]. Influenza epidemics occur in the northern and southern hemispheres during their respective winters[30,31] while increased influenza activity is found to be linked to the rainy season in several tropical populations[32,33]. Other factors linked to influenza epidemics include cold temperatures[34], low indoor humidity[35] and minimal solar radiation[31]. However, a detailed study needs to be done for comprehensive description of the global pattern of seasonal activity of influenza.

3. Common pathogenic viruses associated with respiratory tract infections

Respiratory tract infections are commonly associated with a range of pathogenic viruses and clinical manifestations. There are approximately 200 known respiratory tract viruses of the Adenoviridae, Paroviridae, Orthomyxoviridae, Paramyxoviridae, Picornaviridae and Coronaviridae families associated with respiratory syndromes[36]. Only the common pathogenic viruses associated with respiratory tract infections are described in the following section.

3.1. Influenza virus

Human influenza viruses are enveloped, single-stranded, negative-strand, segmented RNA viruses that belong to the family Orthomyxoviridae. Influenza virus infections may lead to febrile respiratory illnesses and annual epidemics prevailing for about 3–8 weeks[37,38]. Influenza infection can spread globally in the pandemic form through the spread of novel virus types. These novel types of influenza viruses emerge following genetic reassortment of the haemagglutinin (HA) and neuraminidase (NA) genes[39].

Although three subtypes: H1N1, H2N2 and H3N2 were found to be associated with seasonal variations in the last 100 years, a new variant of H1N1 transferred from swine to humans was responsible for a pandemic (worldwide) outbreak in 2009[40]. In addition, the transfer of subtype H5N1 from birds to humans triggered the severe outbreak in Southeast Asia in 2003 and caused significant mortality and morbidity in humans[41]. Although clinicians sometimes use laboratory diagnosis, they often diagnose patients solely based on the presence of influenza-like symptoms. Identification of influenza virus in a hospital environment is important for appropriate control of the spread of infection for example, by droplet isolation. The spread of influenza infection in a hospital can be disastrous for immunocompromised patients for example, transplant recipients or cancer patients, and can cause serious complications leading to death. Transplant recipients may acquire viruses through the donor-derived infections, reactivation of endogenous latent viruses or from the community. Due to the immunocompromised states of these patients, they are susceptible to infections from any opportunistic pathogens. Administration of specific antiviral agents for example, M2 channel inhibitors (amantadine and rimantidine) can be effective in controlling the spread of infections between patients. However, for effective treatment of patients M2 channel inhibitors need to be given within first 24 h of infection. Therefore, a rapid and accurate laboratory diagnosis of influenza virus is of prime importance.

Avian influenza virus (H5N1) was first detected in Hong Kong in 1997[42] and resulted in death for 6 of 18 reported cases. A large number (1.5 million) of infected chickens were culled in Hong Kong to limit the spread of the virus from the infected chickens. Millions of wild and domestic birds were infected by H5N1 in Southeast Asia in 2003. Subsequently, 229 people died out of 359 people who became infected in 14 countries in 2008[43]. Exposure to the infected poultry caused mild to severe respiratory illness due to a new avian influenza A (H7N9) virus was initially reported in China in March 2013. However spread of such infection could not be sustained between persons[43].

3.2. Human parainfluenzavirus (PIV)

Human parainfluenza viruses are enveloped single-stranded negative-sense RNA viruses grouped within the family of Paramyxoviridae. There are four distinct serotypes of PIV associated with human infections[44,45]. The mode of transmission and
pathogenesis of PIVs are similar to those of influenza viruses. PIV1 and PIV2 are found to be the major cause of group in children[46,47] and upper respiratory tract infection (URTI) in all other age groups[45,48]. PIV3 is more likely to be associated with severe lower respiratory tract infection (LRTI) in children. Infections caused by the PIV4 (Subtypes PIVa and PIVb) are less prevalent and less studied compared to the other common viruses of the respiratory tract[44].

3.3. Human respiratory syncytial virus (hRSV)

Human respiratory syncytial virus (hRSV) is a member of Paramyxoviridae and contains a single-stranded negative-sense RNA genome. RSV has been reported to be the major cause of bronchiolitis and pneumonia in children under the age of 2 years[49]. There are two subtypes (A and B) of hRSV found to be associated with infections caused by hRSV. There were over 100,000 hospitalization and 4,500 deaths associated with hRSV infection each year in the USA, with an estimated cost to the economy of $300 million[50].

3.4. Adenovirus

Adenoviruses are double-stranded DNA viruses of the Adenoviridae family and have more than 51 known serotypes which are categorized into six subgenera A to F. Adenoviruses can also cause other types of infections such as conjunctivitis, keratoconjunctivitis, and acute gastroenteritis. Amongst the 51 known serotypes the ones associated with the respiratory tract infections include 1–5, 7, 14, 19 and 37. Adenoviruses generally spread through inhalation of droplet nuclei and infect children under the age of 10 years old[51]. The incidence of adenovirus infections in haematopoietic stem cell transplant patients have been reported by different workers which range between 4.9% and 20.9%[52,53].

3.5. Rhinovirus

Rhinoviruses are single-stranded positive-sense RNA viruses of the Picornaviridae family of which more than 200 serotypes have been identified. Rhinoviruses cause approximately two-third of cases of common cold in humans and have been found associated with asthma exacerbations in chronic lung disease[54]. Rhinoviruses and enteroviruses belong to the same family Picornaviridae and often detected using primers specific for the highly conserved 5' non-coding region (NCR). However, designing a second set of primers targeting the VP1 or VP4 genes can be useful to differentiate between rhinoviruses and enteroviruses. RT-PCR, nucleic acid sequence based amplification (NASBA) have been found to be more sensitive than conventional culture techniques for the detection of rhinoviruses[55].

3.6. Enterovirus and Parechovirus

Enterovirus and Parechovirus are single-stranded positive-sense RNA viruses of the Picornaviridae family. The genus Enterovirus and Parechovirus have been shown to have 63 and 4 distinct members, respectively. Enteroviruses are prevalent worldwide infecting an estimated 1 billion people each year. These infections are common in infants and young children especially under the age of 1 year[56]. Enterovirus infections can cause a range of disease conditions starting from mild respiratory symptoms[57] to serious forms such as poliomyelitis and aseptic meningitis. Although Parechoviruses mainly cause respiratory tract and gastrointestinal infections[58] human parechoviruses can cause acute flaccid paralysis and severe encephalitis.

3.7. Human metapneumovirus

Human metapneumovirus is an RNA virus of the Paramyxoviridae family which was discovered in 2001[4]. It can cause mild to severe respiratory tract infections with symptoms very similar to those caused by hRSV and can lead to the development of bronchiolitis and pneumonia[58]. Human metapneumovirus (hMPV) can cause sporadic infection throughout the year[59] with predominant outbreaks in the winter and spring months of temperate climates[60]. This virus can spread through aerosols, droplets or contaminated surfaces and infect people of all ages primarily infants[61].

3.8. Coronavirus (CoV)

Coronaviruses are single-stranded positive-sense RNA viruses belonging to the Coronaviridae family. Of the five types of coronaviruses reported so far, HCoV-229E and NL-63 belong to Group I whereas OC43, SARS-CoV and HKU1 belong to the Group II CoVs. CoV OC43 and 229E have been found to be associated with respiratory tract infection in immunocompromised children and hospitalized elderly patients[62]. The worldwide outbreak of severe acute respiratory syndrome (SARS) from 2002 to 2003 was associated with SARS-CoV of Group II CoV.

3.9. Human bocavirus (hBoV)

Human bocavirus is a single-stranded DNA virus of the Parvoviridae family. Human bocavirus was discovered by Allander et al. using a large-scale molecular viral screening and DNase Sequence Independent Single Primer Amplification (SISPA) technique[6]. Based on several studies it was found that about 2%–19% of respiratory tract infections were caused by hBoV. Bocavirus infections are detected mainly by molecular techniques[63] as it is not yet possible to grow isolates in cell culture.

3.10. Parvovirus Type 4 and 5 and Mimivirus

Parvovirus type 4 and 5 were found in the serum or plasma samples of 70% of HIV infected patients[64]. Parvoviruses were also found in 4% of manufactured plasma and in healthy blood donors[65]. These types of viruses are considered as potential pathogens of the respiratory tract as are two other parvoviruses, parvovirus B19 and HBoV that are associated with respiratory tract infections.

Mimivirus is a large DNA virus considered as a potential pathogen of the respiratory tract. Antibodies to mimivirus could be detected in 9.7% of community-acquired pneumonia cases compared to 2.3% of healthy controls. Mimivirus DNA was also found in bronchoalveolar lavage specimens from intensive care unit patients[66]. However, in another study mimivirus sequence could not be detected by
real-time PCR in 496 pneumonia patients [67]. Further research is necessary in order to establish the true pathogenicity of these viruses.

4. Conclusion

Respiratory systems are dynamic and exposed to a range of microbiota like viruses, bacteria and chlamydia. Presence of viruses in the respiratory airways is especially important when they are pathogenic. Although around 200 types of viruses of different families are found to be associated with the illness of the respiratory tract all of them are not diagnosed due to the poor multiplex system for diagnosis of a range of viruses. Many of the viruses yet to be diagnosed with improved technology and devices. Future studies may be conducted for the development of new and metagenomic approaches for the diagnosis of novel viruses. It is also important to determine the economic burden of each and every pathogenic viruses. A better understanding of the epidemiology will help prevention and control of virus associated respiratory tract infections.

Conflict of interest statement

We declare that we have no conflict of interest.

References

[1] Schlüer N. Acute respiratory infections: making inroads on a forgotten pandemic. New York: The World Lung Foundation; 2010. [Online] Available from: https://www.scribd.com/document/269305652/Aria [Accessed on 11th November, 2016]
[2] Heikkinen T, Järvinen A. The common cold. Lancer 2003; 361(9351): 51-9.
[3] World Health Organization. Pneumonia: Fact Sheet No. 331. Geneva: World Health Organization; 2014.
[4] van den Hoogen BG, de Jong JC, Silveira HL, Nepomuceno LL, et al. Respiratory viruses in children younger than five years old with acute respiratory disease from 2001 to 2004 in Uberlandia, MG, Brazil. MemInst Oswaldo Cruz 2006; 101(6): 301-6.
[5] Louie JK, Hacker JK, Gonzales R, Mark J, Maselli JH, Yagi S, et al. Characterization of viral agents causing acute respiratory infection in a San Francisco University medical center clinic during the influenza season. Clin Infect Dis 2005; 41(6): 822-8.
[6] Cram P, Blitz SG, Monto A, Fendrick AM. Diagnostic testing for influenza: review of current status and implications of newer treatment options. Am J Manag Care 1999(5)(12): 1555-61.
[7] Templeton K, Simmonds P. Epidemiology and clinical associations of human parechovirus respiratory infections. J Clin Microbiol 2008; 46(10): 3446-53.
[8] Mäkelä MJ, Puhakka T, Saikku P, Leinonen M, Räisänen M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 1998; 36: 539-42.
[9] Mäkelä MJ, Puhakka T, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 1998; 36: 539-42.
[10] World Health Organization. Influenza (seasonal). Geneva: World Health Organization; 2014.
[11] World Health Organization. Pneumonia: Fact Sheet No. 331. Geneva: World Health Organization; 2014.
[12] Massin MM, Montesanti J, Gerard P, Lepage P. Spectrum and frequency of illness presenting to a pediatric emergency department. Acta Clin Belg 2006; 61: 161-5.
[13] World Health Organization. Burden of disease project. Geneva: World Health Organization; 2005.
[14] Nicholson KG, McNally T, Simons P, Stockton JD, Zambon MC. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006; 24: 102-8.
[15] Massin MM, Montesanti J, Gerard P, Lepage P. Spectrum and frequency of illness presenting to a pediatric emergency department. Acta Clin Belg 2006; 61: 161-5.
[16] World Health Organization. Influenza (seasonal). Geneva: World Health Organization; 2014. [Online] Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html [Accessed on 16th November, 2016]
[17] Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S. Vitamin D and cancer: a review of the in vivo epidemiological findings from a retrospective investigation. J Clin Endocrinol Metab 2005; 90(10): 3613-26.
[18] Lipsitch M, Viboud C, Koelle K, Ferrari MJ, Bharti N, Grenfell BT. Influenza seasonality: underlying causes and modeling theories. J Virol 2007; 81: 5429-36.
[19] World Health Organization. Influenza (seasonal). Geneva: World Health Organization; 2014. [Online] Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html [Accessed on 16th November, 2016]
Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. *PLoS One* 2007; 2(12): e1296.

[31] Hope-Simpson RE. The role of season in the epidemiology of influenza. *J Hyg (Lond)* 1981; 86: 35-47.

[32] de Mello WA, de Paiva TM, Ishida MA, Benega MA. Dos Santos MC, Viboud C, et al. The dilemma of influenza vaccine recommendations when applied to the tropics: the Brazilian case examined under alternative scenarios. *PLoS One* 2009; 4(4): e5095.

[33] Moura FE, Perdigao AC, Siqueira MM. Seasonality of influenza in the tropics: a distinct pattern in northeastern Brazil. *Am J Trop Med Hyg* 2009; 81: 180-3.

[34] Davey ML, Reid D. Relationship of air temperature to outbreaks of influenza. *Br J Prev Soc Med* 1972; 26: 28-32.

[35] Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis. *Antonie van Leeuwenhoek* 1962; 28: 221-33.

[36] Abed Y, Boivin G. Treatment of respiratory virus infections. *Antiviral Res* 2006; 70(2): 1-16.

[37] Atmar RL. Influenza viruses. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaffer MA, editors. *Manual of clinical microbiology*. 9th ed. Washington, D.C.: ASM Press; 2007; p. 1340-51.

[38] Harman M. Influenza virus. *Lab Diagn Viral Infect* 1999; 3: 587-602.

[39] Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006; 3: e343.

[40] Al Johani SM, Al Balawi M, Al Alwan B, Al Hefdi R, Hajeer A. Validity of two rapid point of care influenza tests and direct fluorescence assay in comparison of real time PCR for swine of origin Influenza virus. *J Infect Public Health* 2011; 4(1): 7-11.

[41] Adams S, Sandrock C. Avian influenza: update. *Med Princ Pract* 2010; 19(6): 421-32.

[42] Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. *Clin Microbiol Rev* 2006; 19: 614-36.

[43] World Health Organization. Influenza: Avian influenza virus. Geneva: World Health Organization; 2015. [Online] Available from: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/ [Accessed 16th November, 2016]

[44] Beck ET, Henrickson KJ. Molecular diagnosis of respiratory viruses. *Future Microbiol* 2010; 5(6): 901-16.

[45] Henrickson KJ. ParaInfluenza viruses. *Clin Microbiol Rev* 2003; 16(2): 242-64.

[46] Wright PF. Parainfluenza. In: Mandell GL, Bennett JE, Dolin R, editors. *Principles and practice of infectious diseases*. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1998-2003.

[47] Denny FW, Murphy TF, Clyde WA Jr., Collier AM, Henderson FW. Croup: an 11-year study in a pediatric practice. *Pediatrics* 1983; 71(6): 871-6.

[48] Mahony JB. Detection of respiratory viruses by molecular methods. *Clin Microbiol Rev* 2008; 21(4): 716-47.

[49] American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, editor. *Red Book: 2003 report of the committee on infectious diseases*. 26th ed. Elk Grove Village: American Academy of Pediatrics; 2003. p. 523.

[50] Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, editors. *Principles and practice of infectious diseases*. Vol. 2. Philadelphia: Churchill Livingstone; 2000. p. 1782-801.

[51] Fox JP, Brandt CD, Wassermann FE, Hall CE, Spigeland I, Kogon A, et al. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VI. Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. *Am J Epidemiol* 1969; 89: 25-50.

[52] Blanke C, Clark C, Broun R, Tricot G, Cunningham I, Cornetta K, et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. *Am J Med* 1995; 99: 326-8.

[53] Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. *Clin Infect Dis* 1998; 27: 1194-200.

[54] Kling S, Donniger H, Williams Z, Vermeulen J, Weinberg E, Latiff K, et al. Persistence of rhinovirus RNA after asthma exacerbation in children. *Clin Exp Allergy* 2005; 35(5): 672-8.

[55] Loens K, Goossens H, de Laat C, Foolen H, Oudshoorn P, Pattyn S, et al. Detection of rhinoviruses by tissue culture and two independent amplification techniques, nucleic acid sequence-based amplification and reverse transcription-PCR, in children with acute respiratory infections during a winter season. *J Clin Microbiol* 2006; 44: 166-71.

[56] Benschop KS, Schinkel J, Minnaar RP, Pajkrt D, Spanjerberg L, Kraanen HC, et al. Human parechoviruses infections in Dutch children and the association between serotype and disease severity. *Clin Infect Dis* 2006; 42: 204-10.

[57] Cherry JD. Enteroviruses and parechoviruses. In: Feigin RD, Cherry JD, Demmler G, Kaplan SL, editors. *Textbook of pediatric infectious diseases*. 5th ed. Vol. 2. Philadelphia: Saunders; 2004. p. 1984-2041.

[58] Van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WEP, de Groot R, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. *J Infect Dis* 2003; 188: 1571-7.

[59] Williams JV, Harris PA, Tolleson SJ, Halburnt-Rush LL, Pingerhus JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. *N Engl J Med* 2004; 350: 443-50.

[60] Kaida AN, Iritani H, Kubo M, Shiomi UK, Murakami T. Seasonal distribution and phylogenetic analysis of human metapneumovirus among children in Osaka City, Japan. *J Clin Virol* 2006; 35(4): 394-9.

[61] Tang YW, Crowe JE Jr. Respiratory syncytial virus and human metapneumovirus. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaffer MA, editors. *Manual of clinical microbiology*. 9th ed. Washington, D.C.: ASM Press; 2007; p. 1366-77.

[62] Pene F, Merlat A, Vabret A, Rosenberg F, Buszyn A, Dreyfus F, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. *Clin Infect Dis* 2003; 37: 929-32.

[63] Choi JH, Chung YS, Kim KS, Lee WJ, Chung IY, Oh HB, et al. Development of real-time PCR assays for detection and quantification of human bocavirus. *Emerg Infect Dis* 2008; 42: 249-53.

[64] Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV47 and human bocavirus. *J Infect Dis* 2007; 195: 1345-52.

[65] Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. *Transfusion* 2007; 47: 1054-61.

[66] La Scola B, Marrie TJ, Auffray JP, Raoult D. Mimivirus in pneumonia patients. *Emerg Infect Dis* 2005; 11: 449-552.

[67] Dare RK, Humphrey CD, Raoult D, Erdman DD. Screening pneumonia patients for mimivirus. *Emerg Infect Dis* 2008; 14: 465-7.